Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Nuvalent Announces Public Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Details : NVL-520 (zidesamtinib) is a novel brain-penetrant ROS1-selective tyrosine kinase inhibitor. It is being evaluated for ROS1-positive metastatic non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Nuvalent Announces Pricing of Public Offering of Common Stock
Details : The net proceeds will fund clinical development and research of current or additional pipeline candidates including NVL-520, a ROS1-selective tyrosine kinase inhibitor, NVL-655, an ALK-selective inhibitor, and NVL-330, a HER2-selective tyrosine kinase in...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 is a brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, L...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 is a novel brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $230.0 million
Deal Type : Public Offering
Nuvalent Announces Pricing of Public Offering of Common Stock
Details : Nuvalent intend to use the net proceeds, to fund research and clinical development of current or additional pipeline candidates including NVL-520, NVL-655 and NVL-330, and for working capital and other general corporate purposes.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 31, 2022
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $230.0 million
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 is novel brain-penetrant ROS1-selective inhibitor created with the aim to simultaneously overcome the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently av...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 is brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to available ROS1 inhibitors, including tumors with prevalent G2032R resistance mutation and those with S1986Y/F, L2026M, or D2033N res...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 and NVL-655 have been designed to address the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently available ROS1 and ALK kinase inhibitors.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable